Evidence map›Paper›PMID 33739604›Full record

ArticleAnnals of clinical and translational neurology2021

Spinocerebellar ataxia type 14: refining clinicogenetic diagnosis in a rare adult-onset disorder.

Tanja Schmitz-Hübsch, Silke Lux, Peter Bauer, Alexander U Brandt, Elena Schlapakow, Susanne Greschus, Michael Scheel, Hanna Gärtner, Mehmet E Kirlangic, Vincent Gras and 19 more

Open access · goldAbstract read
In one paragraph

Article in Annals of clinical and translational neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Spectrum of Dystonia in Spinocerebellar Ataxia.Tremor and other hyperkinetic movements (New York, N.Y.) · 2026
    Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Novel mutation in exon11 ofFrontiers in genetics · 2023
    Article
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 13 institutions in 3 countries.

Tanja Schmitz-HübschNeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health Berlin, Berlin, Germany.ORCID 0000-0003-4833-5937
Silke LuxDepartment of Psychiatry and Psychotherapy, University Hospital Bonn, Bonn, Germany.
Peter BauerInstitute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.
Alexander U BrandtNeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health Berlin, Berlin, Germany.ORCID 0000-0002-9768-014X
Elena SchlapakowDepartment of Neurology, University Hospital Bonn, Bonn, Germany.
Susanne GreschusDepartment of Radiology, University Hospital Bonn, Bonn, Germany.
Michael ScheelNeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health Berlin, Berlin, Germany.
Hanna GärtnerInstitute of Neuroscience and Medicine (INM-1), Research Centre Juelich, Juelich, Germany.
Mehmet E KirlangicInstitute of Neuroscience and Medicine (INM-1), Research Centre Juelich, Juelich, Germany.
Vincent GrasInstitute of Neuroscience and Medicine (INM-4), Research Centre Juelich, Juelich, Germany.
Dagmar TimmannDepartment of Neurology, Essen University Hospital, University of Duisburg-Essen, Essen, Germany.
Matthis SynofzikDepartment of Neurodegenerative Diseases, Center for Neurology, Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
Alejandro GiorgettiComputational Biophysics, German Research School for Simulation Sciences, and Computational Biomedicine, Institute for Advanced Simulation (IAS-5) and Institute of Neuroscience and Medicine (INM-9), Research Centre Juelich, Juelich, Germany.
Paolo CarloniComputational Biophysics, German Research School for Simulation Sciences, and Computational Biomedicine, Institute for Advanced Simulation (IAS-5) and Institute of Neuroscience and Medicine (INM-9), Research Centre Juelich, Juelich, Germany.
Jon N ShahInstitute of Neuroscience and Medicine (INM-4), Research Centre Juelich, Juelich, Germany.
Ludger SchölsDepartment of Neurodegenerative Diseases, Center for Neurology, Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
Ute KoppKlinik und Hochschulambulanz für Neurologie, Charité -Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.
Lisa BußeniusInstitute of Neuroscience and Medicine (INM-1), Research Centre Juelich, Juelich, Germany.
Timm OberwahrenbrockNeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health Berlin, Berlin, Germany.
Hanna ZimmermannNeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health Berlin, Berlin, Germany.
Caspar PfuellerNeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health Berlin, Berlin, Germany.
Ella-Maria KadasNeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health Berlin, Berlin, Germany.
Maria RönnefarthKlinik und Hochschulambulanz für Neurologie, Charité -Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.
Anne-Sophie GroschKlinik und Hochschulambulanz für Neurologie, Charité -Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.
Matthias EndresNeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health Berlin, Berlin, Germany.ORCID 0000-0001-6520-3720
Katrin AmuntsInstitute of Neuroscience and Medicine (INM-1), Research Centre Juelich, Juelich, Germany.
Friedemann PaulNeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health Berlin, Berlin, Germany.
Sarah DossKlinik und Hochschulambulanz für Neurologie, Charité -Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.
Martina MinneropInstitute of Neuroscience and Medicine (INM-1), Research Centre Juelich, Juelich, Germany.ORCID 0000-0003-1365-5236
Humboldt-Universität zu Berlin · DEForschungszentrum Jülich · DEGerman Center for Neurodegenerative Diseases · DEUniversity Hospital Bonn · DECentogene (Germany) · DEEssen University Hospital · DEGerman Research School for Simulation Sciences · DENebraska Medical Center · USTechnische Universität Ilmenau · DEUniversität Hamburg · DEUniversity of Bonn · DEUniversity of California, Irvine · USUniversity of Verona · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesGenetic variant classification is a challenge in rare adult-onset disorders as in SCA-PRKCG (prior spinocerebellar ataxia type 14) with mostly private conventional mutations and nonspecific phenotype. We here propose a refined approach for clinicogenetic diagnosis by including protein modeling and provide for confirmed SCA-PRKCG a comprehensive phenotype description from a German multi-center cohort, including standardized 3D MR imaging.

methodsThis cross-sectional study prospectively obtained neurological, neuropsychological, and brain imaging data in 33 PRKCG variant carriers. Protein modeling was added as a classification criterion in variants of uncertain significance (VUS).

resultsOur sample included 25 cases confirmed as SCA-PRKCG (14 variants, thereof seven novel variants) and eight carriers of variants assigned as VUS (four variants) or benign/likely benign (two variants). Phenotype in SCA-PRKCG included slowly progressive ataxia (onset at 4-50 years), preceded in some by early-onset nonprogressive symptoms. Ataxia was often combined with action myoclonus, dystonia, or mild cognitive-affective disturbance. Inspection of brain MRI revealed nonprogressive cerebellar atrophy. As a novel finding, a previously not described T2 hyperintense dentate nucleus was seen in all SCA-PRKCG cases but in none of the controls.

interpretationIn this largest cohort to date, SCA-PRKCG was characterized as a slowly progressive cerebellar syndrome with some clinical and imaging features suggestive of a developmental disorder. The observed non-ataxia movement disorders and cognitive-affective disturbance may well be attributed to cerebellar pathology. Protein modeling emerged as a valuable diagnostic tool for variant classification and the newly described T2 hyperintense dentate sign could serve as a supportive diagnostic marker of SCA-PRKCG.

Indexed as

AdultAge of OnsetCross-Sectional StudiesDisease ProgressionFemaleHumansMaleProspective StudiesProtein Kinase CSpinocerebellar AtaxiasProtein Kinase Cprotein kinase C gamma

Identifiers

PMID33739604
PMCPMC8045942
OpenAlexW3136338554

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.